Effects of aspirin combined with cilostazol on thromboangiitis obliterans in diabetic patients

Yong,Jun; Zhang,Shaomei; Gao,Yan; Guo,Wenchen; Shi,Peixia; Zhou,Qinglin

doi:10.3892/etm.2018.6833

Effects of aspirin combined with cilostazol on thromboangiitis obliterans in diabetic patients

Authors:
- Jun Yong
- Shaomei Zhang
- Yan Gao
- Wenchen Guo
- Peixia Shi
- Qinglin Zhou
View Affiliations

Affiliations: Department of Vascular Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China, Department of Pharmacy, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China, Department of Laboratory Medicine, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China, Department of Internal Medicine, People's Hospital of Zhangqiu, Jinan, Shandong 250200, P.R. China, Department of Cardiology, People's Hospital of Zhangqiu, Jinan, Shandong 250200, P.R. China, Department of Blood Transfusion, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: October 8, 2018 https://doi.org/10.3892/etm.2018.6833
Pages: 5041-5046
Copyright: © Yong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study explored the effects of aspirin combined with cilostazolin in the treatment of diabetic patients with thromboangiitis obliterans and the effects on the related inflammatory factors. A total of 90 diabetic patients with thromboangiitis obliterans admitted to Weifang People's Hospital from August 2015 to June 2017 were selected and divided into the control group (n=45) and the combination group (n=45). Patients in the control group were given aspirin, and those in the combination group were given aspirin combined with cilostazol. Before treatment and 6 weeks after treatment, the clinical data including ankle‑brachial index (ABI), 6‑min walk test (6MWT) and test data including serum inflammatory factors interleukin (IL)‑8, IL‑6 and matrix metalloprotease (MMP)‑2 and MMP‑9 of the two groups were collected for quantitative and statistical analysis. Compared with those in the control group, the ABI and 6MWT in the combination group could be effectively reduced, and the differences were statistically significant (P<0.05). At the same time, cilostazol combined with aspirin could effectively reduce the levels of serum inflammatory factors MMP‑2 and MMP‑9 in patients, except for nitric oxide (NO), and the differences were statistically significant (P<0.05). Compared with that before treatment, the control and the combination group can significantly improve the clinical symptoms of the patients, and aspirin combined with cilostazol can effectively improve the clinical curative effect of diabetic patients with thromboangitis obliterans and delay the progression of the disease.

View Figures

View References

1	ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 2:349–360. 1988.PubMed/NCBI
2	Weber AA, Przytulski B, Schanz A, Hohlfeld T and Schrör K: Towards a definition of aspirin resistance: A typological approach. Platelets. 13:37–40. 2002. View Article : Google Scholar : PubMed/NCBI
3	Ji AL, Chen WW and Huang WJ: Clinical study on influences of enteric coated aspirin on blood pressure and blood pressure variability. Eur Rev Med Pharmacol Sci. 20:5017–5020. 2016.PubMed/NCBI
4	Olszanecka A, Olszanecki R, Korbut R and Kawecka-Jaszcz K: Aspirin resistance - pharmacological mechanisms and clinical implications. Kardiol Pol. 62:87–92. 2005.(In Polish). PubMed/NCBI
5	Eichhorn J, Sima D, Lindschau C, Turowski A, Schmidt H, Schneider W, Haller H and Luft FC: Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci. 315:17–23. 1998. View Article : Google Scholar : PubMed/NCBI
6	ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, . ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 166:111–117. 2002. View Article : Google Scholar : PubMed/NCBI
7	Wan J, Yang Y, Ma ZH, Sun Y, Liu YQ, Li GJ and Zhang GM: Autologous peripheral blood stem cell transplantation to treat thromboangiitis obliterans: Preliminary results. Eur Rev Med Pharmacol Sci. 20:509–513. 2016.PubMed/NCBI
8	Kobayashi M, Ito M, Nakagawa A, Nishikimi N and Nimura Y: Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vasc Surg. 29:451–458. 1999. View Article : Google Scholar : PubMed/NCBI
9	Kimura A, Kobayashi Y, Takahashi M, Ohbuchi N, Kitamura H, Nakamura T, Satoh M, Sasaoka T, Hiroi S, Arimura T, et al: MICA gene polymorphism in Takayasu's arteritis and Buerger's disease. Int J Cardiol. 66 Suppl 1:S107–S113; discussion S115. 1998. View Article : Google Scholar : PubMed/NCBI
10	Sadik NA, Mohamed WA and Ahmed MI: The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Mol Cell Biochem. 359:73–81. 2012. View Article : Google Scholar : PubMed/NCBI
11	Laight DW, Carrier MJ and Anggård EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev. 15:274–282. 1999. View Article : Google Scholar : PubMed/NCBI
12	O'Brien JR: Shear-induced platelet aggregation. Lancet. 335:711–713. 1990. View Article : Google Scholar : PubMed/NCBI
13	Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H, Tomita M and Kawashima S: Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron. 85:81–85. 2000. View Article : Google Scholar : PubMed/NCBI
14	Avogaro A, Piarulli F, Valerio A, Miola M, Calveri M, Pavan P, Vicini P, Cobelli C, Tiengo A, Calò L, et al: Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes. 46:1040–1046. 1997. View Article : Google Scholar : PubMed/NCBI
15	Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G and Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 97:2601–2610. 1996. View Article : Google Scholar : PubMed/NCBI
16	Shimoyama Y, Taki K, Mitsuda Y, Tsuruta Y, Hamajima N and Niwa T: KLOTHO gene polymorphisms G-395A and C1818T are associated with low-density lipoprotein cholesterol and uric acid in Japanese hemodialysis patients. Am J Nephrol. 30:383–388. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zheng AS, Churilov L, Colley RE, Goh C, Davis SM and Yan B: Association of aspirin resistance with increased stroke severity and infarct size. JAMA Neurol. 70:208–213. 2013. View Article : Google Scholar : PubMed/NCBI
18	Paez Espinosa EV, Murad JP and Khasawneh FT: Aspirin: Pharmacology and clinical applications. Thrombosis. 2012:1731242012. View Article : Google Scholar : PubMed/NCBI
19	Rydzewski A, Urano T, Hachiya T, Kaneko H, Baba S, Takada Y and Takada A: The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res. 84:445–452. 1996. View Article : Google Scholar : PubMed/NCBI
20	Ishibashi H, Hayakawa N, Yamamoto H, Nishikimi N, Yano T and Nimura Y: Thoracoscopic sympathectomy for Buerger's disease: A report on the successful treatment of four patients. Surg Today. 25:180–183. 1995. View Article : Google Scholar : PubMed/NCBI